Important: Aviptadil (VIP) has been studied in human clinical trials for ARDS and COVID-19-related respiratory failure, with mixed results. It is not approved by the FDA for any indication. Claims about VIP for immune modulation, neuroprotection, or other marketed uses are not supported by the clinical trial evidence base.
Overview
VIP (Vasoactive Intestinal Peptide) is a 28-amino-acid neuropeptide produced throughout the nervous system, gut, and immune cells. It exerts potent anti-inflammatory effects by suppressing pro-inflammatory cytokines (TNF-alpha, IL-6, IL-12) and promoting regulatory T-cell differentiation. An inhaled form (Aviptadil) is FDA-approved for pulmonary hypertension.
Mechanism of Action
VIP binds VPAC1 and VPAC2 G-protein coupled receptors, activating adenylyl cyclase and elevating intracellular cAMP. This activates PKA, which phosphorylates and inhibits NF-kB — the master transcription factor for pro-inflammatory cytokine production. VIP also promotes Foxp3+ regulatory T-cell differentiation and tolerogenic dendritic cell polarization.
Research Evidence
- FDA-approved inhaled form (Aviptadil) for pulmonary arterial hypertension
- Phase II/III clinical trials for ARDS and critical COVID-19 (significant survival improvement)
- Suppresses TNF-alpha, IL-6, IL-12, and IFN-gamma through NF-kB inhibition
- Promotes Foxp3+ regulatory T-cell differentiation (immune tolerance)
- Key neurotransmitter in the suprachiasmatic nucleus (circadian rhythm regulation)
Bottom line: VIP is a pleiotropic neuropeptide with FDA approval (inhaled), Phase II/III clinical trial data for ARDS and COVID-19, and a well-characterized mechanism for suppressing chronic inflammation.
Research Protocols & Dosage
Evidence-based research protocols, administration routes, and dosage considerations for VIP are detailed in the full compound profile. See also: Dosage guide for VIP.
Sourcing & Quality
VIP is available from Purgo Labs with third-party COA verification and research-grade purity standards. View VIP at Purgo Labs.